Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma

Cancer

Volumn 116, Issue 11, 2010, Pages 2655-2664

  Ruan, Jia ^a   Martin, Peter ^a   Coleman, Morton ^a   Furman, Richard R ^a   Cheung, Ken ^b   Faye, Adam ^a   Elstrom, Rebecca ^a   Lachs, Mark ^a   Hajjar, Katherine A ^a   Leonard, John P ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b Columbia University ^*  (United States)

Author keywords

Angiogenesis; Elderly patients; Etoposide; Metronomic therapy; Prednisone; Procarbazine and cyclophosphamide; Recurrent mantle cell lymphoma

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA SMOOTH MUSCLE ACTIN; BORTEZOMIB; CD34 ANTIBODY; CYCLOPHOSPHAMIDE; ETOPOSIDE; PODOPLANIN; PREDNISONE; PROCARBAZINE; RITUXIMAB; THALIDOMIDE; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANEMIA; ANGIOGENESIS; ARTICLE; B LYMPHOCYTE; BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER SIZE; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; CONTROLLED STUDY; COUGHING; CYTOPENIA; DEEP VEIN THROMBOSIS; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ENDOTHELIUM CELL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GERIATRIC PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; LOW DRUG DOSE; LUNG EMBOLISM; LYMPHANGIOGENESIS; MALE; MANTLE CELL LYMPHOMA; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUROPATHY; NEUTROPENIA; NEUTROPHIL COUNT; PHENOTYPE; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RECURRENT CANCER; RETINITIS; SCORING SYSTEM; THROMBOCYTOPENIA; THROMBOSIS PREVENTION; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; ETOPOSIDE; FEMALE; HUMANS; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PREDNISONE; PROCARBAZINE; QUALITY OF LIFE; RECURRENCE; THALIDOMIDE; TREATMENT OUTCOME;

EID: 77952839682     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25055     Document Type: Article

References (26)

1. Fisher RI, Dahlberg S, Nathwani BN, Banks PM, Miller TP, Grogan TM. A clinical analysis of 2 indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study. Blood. 1995;85:1075-1082.
2. Howard OM, Gribben JG, Neuberg DS, et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol. 2002;20: 1288-1294.
3. Lenz G, Dreyling M, Hoster E, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol. 2005;23:1984-1992.
4. Romaguera JE, Fayad L, Rodriguez MA, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper- CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol. 2005;23:7013-7023.
5. Dreyling M, Lenz G, Hoster E, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL networks. Blood. 2005;105:2677-2684. (Pubitemid 40450320)
6. Herrmann A, Hoster E, Zwingers T, et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol. 2009;27:511-518.
7. Fisher RI, Bernstein SH, Kahl BS, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2006;24:4867-4874.
8. Witzig TE, Geyer SM, Ghobrial I, et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol. 2005;23:5347-5356. (Pubitemid 46206988)
9. Hess G, Romaguera JE, Verhoef G, et al. Phase III study of patients with relapsed, refractory mantle cell lymphoma treated with temsirolimus compared with investigator's choice [abstract]. J Clin Oncol. 2008;26(May 20 suppl). Abstract 8513.
10. Wiernik PH, Lossos IS, Tuscano JM, et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2008;26:4952-4957.
11. Czuczman MS, Reeder CB, Polikoff J, et al. International study of lenalidomide in relapsed/refractory aggressive non- Hodgkin's lymphoma [abstract]. J Clin Oncol. 2008;26(May 20 suppl). Abstract 8509.
12. Habermann T, Lossos IS, Justice G, et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol. 2009;145:344-349.
13. Coleman M, Martin P, Ruan J, et al. Low-dose metronomic, multidrug therapy with the PEP-C oral combination chemotherapy regimen for mantle cell lymphoma. Leuk Lymphoma. 2008;49:447-450. (Pubitemid 351305692)
14. Kaufmann H, Raderer M, Wohrer S, et al. Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. Blood. 2004;104: 2269-2271. (Pubitemid 39331822)
15. Forstpointner R, Unterhalt M, Dreyling M, et al. Maintenance therapy with rituximab leads to significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood. 2006;108:4003-4008. (Pubitemid 44920177)
16. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non- Hodgkin's lymphomas. J Clin Oncol. 1999;17:1244-1253. (Pubitemid 29162950)
17. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J ClinOncol. 1993;11:570-579. (Pubitemid 23071057)
18. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 2004;4:423-436.
19. Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer. 2004;4:314-322. (Pubitemid 38525287)
20. Coleman M, Martin P, Ruan J, et al. The PEP-C (prednisone, etoposide, procarbazine, and cyclophosphamide) oral combination chemotherapy regimen for relapsing/refractory lymphoma: low dose metronomic, multidrug therapy. Cancer. 2008;112:2228-2232.
21. Buckstein R, Kerbel RS, Shaked Y, et al. High-dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma. Clin Cancer Res. 2006;12:5190-5198.
22. Bertolini F, Paul S, Mancuso P, et al. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res. 2003;63:4342-4346. (Pubitemid 36951001)
23. Shaked Y, Ciarrocchi A, Franco M, et al. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science. 2006;313:1785-1787. (Pubitemid 44454154)
24. Mancuso P, Colleoni M, Calleri A, et al. Circulating endothelial- cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood. 2006;108:452-459. (Pubitemid 44061341)
25. Stopeck AT, Unger JM, Rimsza LM, et al. A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest Oncology Group Study S0108. Leuk Lymphoma. 2009;50:728-735.
26. Fragoso R, Pereira T, Wu Y, Zhu Z, Cabecadas J, Dias S. VEGFR-1 (FLT-1) activation modulates acute lymphoblastic leukemia localization and survival within the bone marrow, determining the onset of extramedullary disease. Blood. 2006;107:1608-1616. (Pubitemid 43245539)